

# Resource Summary Report

Generated by [PRECISE-TBI](#) on Jul 31, 2026

## BD Biosciences: Canto II Flow Cytometer

RRID:SCR\_018056

Type: Tool

---

### Proper Citation

BD Biosciences: Canto II Flow Cytometer (RRID:SCR\_018056)

---

### Resource Information

**URL:** <https://www.bdbiosciences.com/en-us/instruments/research-instruments/research-cell-analyzers/facscanto-ii>

**Proper Citation:** BD Biosciences: Canto II Flow Cytometer (RRID:SCR\_018056)

**Description:** Benchtop flow cytometer features reliable performance and accurate results for experiments requiring up to 10 parameters. Fixed alignment flow cell minimizes startup time and improves reproducibility. Patented optical design maximizes signal detection and increases sensitivity and resolution for each color in multicolor assay.

**Synonyms:** Canto II

**Resource Type:** instrument resource

**Keywords:** ABRF, Flow Cytometer, benchtop analyzer, cell analyzer, flow cytometry, multicolor analysis, BD FACSCanto II, instrument, equipment

**Specification URL:** [https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR\\_018056.pdf](https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_018056.pdf)

**Resource Name:** BD Biosciences: Canto II Flow Cytometer

**Resource ID:** SCR\_018056

**Alternate IDs:** Model\_Number\_Canto II

**Alternate URLs:** [https://www.bdbiosciences.com/content/dam/bdb/marketing-documents/BD\\_FACSCanto\\_II\\_brochure.pdf](https://www.bdbiosciences.com/content/dam/bdb/marketing-documents/BD_FACSCanto_II_brochure.pdf)

**Record Creation Time:** 20220129T080338+0000

**Record Last Update:** 20260725T190839+0000

---

### Ratings and Alerts

No rating or validation information has been found for BD Biosciences: Canto II Flow Cytometer.

No alerts have been found for BD Biosciences: Canto II Flow Cytometer.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 46 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [PRECISE-TBI](#) .

Stern YE, et al. (2026) Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. *Cancer research*, 86(2), 485.

Hoffmann J, et al. (2025) Steatohepatitis-induced vascular niche alterations promote melanoma metastasis. *Cancer & metabolism*, 13(1), 5.

Bleve A, et al. (2025) ROR? Bridges Cancer-Driven Lipid Dysmetabolism and Myeloid Immunosuppression. *Cancer discovery*, 15(7), 1505.

Martínez Villarreal A, et al. (2025) Memory T-Cell Phenotype in Cutaneous T-Cell Lymphoma Is Modified by Germline Gene Gametocyte Specific Factor 1. *Experimental dermatology*, 34(5), e70123.

Landi D, et al. (2025) A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function. *Cancer research communications*, 5(3), 527.

Shia CS, et al. (2025) Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody-Drug Conjugate. *Molecular cancer therapeutics*, 24(12), 1938.

Choe M, et al. (2025) Preclinical Evaluation of Folate Receptor-? Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma. *Cancer research communications*, 5(9), 1701.

Verdegaal EME, et al. (2025) Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFN?. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(13), 2628.

Jha V, et al. (2025) Substitution of Glutamic Acid at Position 71 of DR?1\*04:01 and Collagen-Specific Tolerance Without Alloreactivity. *Arthritis & rheumatology (Hoboken, N.J.)*, 77(5), 526.

Boccardo S, et al. (2025) Dynamics of tissue repair regulatory T cells and damage in acute *Trypanosoma cruzi* infection. *PLoS pathogens*, 21(1), e1012906.

Ku G, et al. (2025) A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(23), 4944.

Song Z, et al. (2025) CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice. *Cancer immunology research*, 13(8), 1246.

Killarney ST, et al. (2025) PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State. *Cancer discovery*, 15(3), 595.

Xiong W, et al. (2025) Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(10), 1856.

Eguchi S, et al. (2025) CXCL10-induced chemotaxis of ex vivo-expanded natural killer cells combined with NKTR-255 enhances anti-tumor efficacy in osteosarcoma. *Molecular therapy. Oncology*, 33(4), 201051.

Zhang Y, et al. (2025) Deprivation of EGFR signal causes senolysis in PDAC with CDK4/6 inhibition. *Cell death and differentiation*.

Lee W, et al. (2025) Protocol for assessing mobilization of peritoneal B cells to the pre-metastatic omentum in an orthotopic mouse model of ovarian cancer. *STAR protocols*, 6(2), 103806.

Tasis A, et al. (2024) Single-Cell Analysis of Bone Marrow CD8+ T Cells in Myeloid Neoplasms Reveals Pathways Associated with Disease Progression and Response to Treatment with Azacitidine. *Cancer research communications*, 4(12), 3067.

Willems M, et al. (2024) The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity. *EBioMedicine*, 109, 105418.

Wang CY, et al. (2024) UB-612 pan-SARS-CoV-2 T cell immunity-promoting vaccine protects against COVID-19 moderate-severe disease. *iScience*, 27(2), 108887.